By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Willemstraat 5

Breda    4811 AH  The Nederlands
Phone: 31-0-10-763-030-488 Fax: n/a


argenx a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe auto-immune diseases and cancer. We are focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. Our ability to execute on this focus is enabled by our suite of differentiated technologies. Our SIMPLE AntibodyTM Platform, based on the powerful llama immune system, allows us to exploit novel and complex targets, and our three antibody engineering technologies are designed to enable us to expand the therapeutic index of our product candidates.




CEO: Tim Van Hauwermeiren

CFO: Eric Castaldi

CSO: Hans de Haard

CDO: Torsten Dreier

CMO: Nicolas Leupin


Please click here for Argenx job opportunities.


Please click here for clinical trial information.

Key Statistics

Ownership: Private

Web Site: Argenx


Company News
Staten Biotech Exercises Option To Develop Therapeutic SIMPLE Antibody For Dyslipidemia From Argenx 3/6/2017 8:59:00 AM
AbbVie (ABBV) Gets First Dibs on arGEN-X's Immuno-Oncology Drug in Deal Worth $685 Million 4/21/2016 5:59:10 AM
arGEN-X Reports Fourth Quarter Business Update And Full Year 2015 Financial Results 3/11/2016 9:00:53 AM
arGEN-X Opens Clinical Trial Sites In South Korea For ARGX-111 Program 2/18/2016 8:42:01 AM
arGEN-X To Present At The LEERINK Partners 5th Annual Global Healthcare Conference 2/5/2016 8:52:59 AM
arGEN-X Receives Milestone Payment In LEO Pharma Collaboration 2/2/2016 9:10:02 AM
arGEN-X, LEO Pharma Forge $116 Million Skin Pact 5/22/2015 5:37:49 AM
Forbion Announces Closing Of Initial Public Offering Of Portfolio Company arGEN-X 7/9/2014 9:09:43 AM
Dutch Biotech arGEN-X Plans To Go Public In Brussels 6/10/2014 7:26:33 AM
arGEN-X Inks Long-Term Alliance With Shire Pharmaceuticals (SHPG) Worth $20.4 Million 6/4/2014 6:31:23 AM